Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Core Insights - Werewolf Therapeutics is advancing its clinical programs with significant milestones expected in 2025, including data from ongoing trials for WTX-124 and WTX-330 [1][2][3] Clinical Development - Data from the Phase 1/1b clinical trial for WTX-124 as a monotherapy is expected in the first half of 2025, which will guide regulatory engagement for potential registrational pathways [1][2] - Combination data for WTX-124 with pembrolizumab is anticipated in the fourth quarter of 2025 [1][2] - A Phase 1/2 dose and regimen-finding clinical trial for WTX-330 is set to begin in the first quarter of 2025 [1][2][11] Financial Guidance - The company expects its cash and cash equivalents to fund operations through at least the second quarter of 2026 [8] Product Details - WTX-124 is being developed as a conditionally activated IL-2 INDUKINE molecule for multiple solid tumor types, showing promising activity and improved tolerability compared to high-dose IL-2 [4][9] - The recommended dose for WTX-124 in monotherapy expansion arms is 18 mg administered intravenously every two weeks [4] - WTX-330 is an IL-12 INDUKINE molecule aimed at treating immunotherapy-resistant cancers [2][4] Strategic Outlook - The company plans to engage with regulators regarding potential accelerated approval strategies for WTX-124 based on interim data [5] - Ongoing preclinical work will support IND-stage programs and the company seeks strategic partnerships to advance these initiatives [6][7]